• Publications
  • Influence
Guidelines for the Early Management of Adults With Ischemic Stroke
Purpose— Our goal is to provide an overview of the current evidence about components of the evaluation and treatment of adults with acute ischemic stroke. The intended audience is physicians and ot...
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
Despite an increased frequency of early symptomatic intracranial hemorrhage, treatment with IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusion significantly improved clinical outcome at 90 days.
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
In patients with cryptogenic stroke or TIA who had a patent foramen ovale, closure with a device did not offer a greater benefit than medical therapy alone for the prevention of recurrent stroke orTIA.
Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association
In 1994, a panel appointed by the Stroke Council of the American Heart Association authored guidelines for the management of patients with acute ischemic stroke.1 After the approval of the use of
Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke
This document serves to standardize reporting terminology and includes pretreatment assessment, neurologic evaluation with the NIH Stroke Scale score, imaging evaluation, occlusion sites, perfusion grades, follow-up imaging studies, and neurologic assessments, and suggestions for uniform reporting standards for such trials.
Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
It is indicated that site of occlusion, time to recanalization, and time to treatment are important variables in acute stroke intervention with this agent.
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase
Intravenous desmoteplase administered 3 to 9 hours after acute ischemic stroke in patients selected with perfusion/diffusion mismatch is associated with a higher rate of reperfusion and better clinical outcome compared with placebo.
Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
A small proportion of patients admitted with acute ischemic stroke in Cleveland received tPA; they experienced a high rate of ICH and in-hospital mortality was significantly higher among patients treated with tPA, and with mortality predicted by a model.
Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion–diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind,
The DIAS-2 study did not show a benefit of desmoteplase given 3-9 h after the onset of stroke, and the high response rate in the placebo group could be explained by the mild strokes recorded (low baseline NIHSS scores, small core lesions, and small mismatch volumes that were associated with no vessel occlusions), which possibly reduced the potential to detect any effect.
Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.
This special report provides information about the current management of acute ischemic stroke and provides recommendations for initial care based on currently available data from clinical trials and predicts that in the future, many therapies for stroke will be linked to very early intervention.